WAYNE, Pa.--(BUSINESS WIRE)--Aug. 7, 2006--Covalent Group, Inc. (Nasdaq: CVGR - News), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, today announced the signing of a $1.7 million contract for a Phase 2 clinical trial designed to test the hypothesis that aggressive anti-microbial therapy can beneficially impact the progression of atherosclerosis in subjects with known vascular disease. Atherosclerosis is a disease affecting the arterial blood vessels throughout the body.
